Key statistics
As of last trade Cyclacel Pharmaceuticals Inc (UXI:STU) traded at 0.855, 0.59% above its 52-week low of 0.85, set on Sep 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.86 |
---|---|
High | 0.865 |
Low | 0.855 |
Bid | 0.855 |
Offer | 0.95 |
Previous close | 0.86 |
Average volume | 74.22 |
---|---|
Shares outstanding | 1.97m |
Free float | 1.87m |
P/E (TTM) | -- |
Market cap | 1.95m USD |
EPS (TTM) | -16.14 USD |
Data delayed at least 15 minutes, as of Sep 24 2024.
More ▼
- Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
- Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
- Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
- Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
- Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
- Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
- Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
- Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
More ▼